Paper on Entrainment in Mice by CT1500 Published Paper published on Circadian Entrainmanet in Mice by CT1500 The paper shows in vivo that a single dose of CT1500 enhances re-entrainment to a shifted light dark cycle in a dose-dependent manner in mice and also phase...
CT1500 Phase 1 Study CT1500 Phase 1 Study Circadian Therapeutics announces the first subject recruited to Phase I study for CT-1500, marks move to a clinical stage company • First subject dosed for Phase I study• CT-1500 being developed to treat Non-24 Sleep-Wake...
Circadian Therapeutics and Arquimea Collaboration Circadian Therapeutics and ARQUIMEA sign a collaboration agreement for the development of casein kinase 1 inhibitors for the treatment of diseases affecting the nervous system Co-development of molecules as an...
